Vimian Group acquires veterinary allergy business in the UK
Vimian Group has acquired the veterinary allergy division of AvactaGroup plc in the UK, to strengthen Vimian’s position within veterinary allergy diagnostics and treatments in the UK. The business had revenues of GBP 1.6 million in 2021.
Vimian Group’s Specialty Pharma segment Nextmune has acquired the veterinary allergy division, Avacta Animal Health, from AvactaGroup plc. Avacta Animal Health provides veterinary allergy diagnostic solutions through its laboratory in Wetherby (UK) and re-sells Nextmune’s immunotherapy products to veterinary clinics across the UK. The business division also provides testing kits to veterinary laboratories in other European countries. The acquisition is a carve-out from AvactaGroup plc, a UK-based company focused on diagnostic solutions for human health.
“This acquisition significantly strengthens Nextmune’s competitive position in the UK. With our own laboratory for veterinary allergy diagnostics in the country and a full-service offering covering all veterinary dermatology needs, we see significant opportunities to accelerate sales and improve customer experience in the UK. The cross-selling opportunities via this business existing customer base as well as the increased laboratory capacity for Nextmune are also key components in driving incremental growth, says Magnus Kjellberg, CEO of Vimian’s Specialty Pharma segment Nextmune.
Avacta Animal Health will be integrated into Nextmune UK, led by Country Manager Cathy Gurney. The acquisition was consolidated into Vimian’s Specialty Pharma segment on 15 March, 2022.
